FME Stock Chart & Stats
CHF36.28
-CHF75.28(-100.00%)
At close: 4:00 PM EDT
CHF36.28
-CHF75.28(-100.00%)
Day’s Range― - ―
52-Week RangeCHF31.91 - CHF97.00
Previous CloseN/A
Volume400.00
Average Volume (3M)0.00
Market Cap
CHF10.30B
Enterprise ValueCHF20.90B
Total Cash (Recent Filing)CHF1.24B
Total Debt (Recent Filing)CHF11.03B
Price to Earnings (P/E)12.8
Beta-0.15
Next Earnings
Aug 04, 2026EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend Yield3.42%
Share Statistics
EPS (TTM)3.28
Shares Outstanding268,564,640
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF35.23Price Target Upside-2.88% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering11
EPS Forecast (FY)3.68
Revenue Forecast (FY)CHF17.80B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelFresenius Medical Care’s dual segments (care delivery and products) create durable revenue synergies: clinics generate recurring demand for consumables and services while product sales extend to external providers. This vertical integration supports steady consumable volumes and cross-selling over time, reducing reliance on any single channel for durable cash flows.
Strong Free Cash Flow GenerationConsistent FCF at scale provides durable financial flexibility: it funds maintenance capex, dividends, and debt paydown without recurring equity raises. The company’s positive FCF conversion cushions earnings volatility and enables strategic investments or de-leveraging that support long-term stability and shareholder returns.
Improving Leverage ProfileReduction in leverage and recovering ROE represent structural de-risking: lower debt ratios improve financial resilience to reimbursement shifts and funding cost shocks, expand capacity for targeted investments or M&A, and enhance credit profile—supporting the company’s ability to execute medium-term strategic plans.
Bears Say
Stagnant Top-lineA flat-to-declining revenue trend constrains sustainable earnings growth absent material pricing, volume, or M&A catalysts. For a business tied to patient volumes and reimbursements, prolonged top-line stagnation limits scalability of operating leverage and makes margin expansion and long-term EPS growth harder to achieve.
Moderate And Variable MarginsRelatively modest margins and historical volatility reduce earnings resilience versus peers. Profitability is sensitive to input costs, clinic utilization and product pricing; without sustained margin improvement, free cash flow and return metrics remain vulnerable to reimbursement or cost pressures over the medium term.
Payor/regulatory SensitivityHeavy dependence on government and private insurer reimbursement creates persistent regulatory and pricing risk. Structural changes in payor policies, reimbursement rates, or coverage rules can materially alter revenues and margins; this exposure limits pricing flexibility and makes long-term projections contingent on external policy developments.
FME FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was CHF31.91 and its highest was CHF97.00 in the past 12 months.
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
Fresenius Medical Care AG & Co. KGaA’s market cap is CHF10.30B.
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Aug 04, 2026 which is in 26 days.
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Fresenius Medical Care AG & Co. KGaA released its earnings results on May 05, 2026. The company reported CHF0.839 earnings per share for the quarter, missing the consensus estimate of CHF0.934 by -CHF0.094.
Is Fresenius Medical Care AG & Co. KGaA overvalued?
According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued.
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of CHF1.375 which represents an annual dividend yield of 3.42%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 0.96.
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
Fresenius Medical Care AG & Co. KGaA has 268,564,640 shares outstanding.
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Fresenius Medical Care AG & Co. KGaA reported an EPS of CHF0.839 in its last earnings report, missing expectations of CHF0.934. Following the earnings report the stock price went down -8.743%.
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
Currently, no hedge funds are holding shares in CH:FME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
CHF35.23 (-2.88% Downside)
CHF35.23 (-2.88% Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.62%
12-Months-Change
Fundamentals
Return on Equity
7.16%
Trailing 12-Months
Asset Growth
-3.87%
Trailing 12-Months
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
FME Stock 12 Month Forecast
Average Price Target
CHF35.23
▼(-2.88% Downside)
Technical Analysis
Options Prices
Currently, No data available
---






